Pharmx Technologies Ltd (PHX) - Net Assets
Based on the latest financial reports, Pharmx Technologies Ltd (PHX) has net assets worth AU$15.93 Million AUD (≈ $11.27 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$18.82 Million ≈ $13.32 Million USD) and total liabilities (AU$2.90 Million ≈ $2.05 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PHX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$15.93 Million |
| % of Total Assets | 84.61% |
| Annual Growth Rate | 3.7% |
| 5-Year Change | -30.54% |
| 10-Year Change | -19.99% |
| Growth Volatility | 849.76 |
Pharmx Technologies Ltd - Net Assets Trend (1989–2025)
This chart illustrates how Pharmx Technologies Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Pharmx Technologies Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Pharmx Technologies Ltd (1989–2025)
The table below shows the annual net assets of Pharmx Technologies Ltd from 1989 to 2025. For live valuation and market cap data, see market value of Pharmx Technologies Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$15.93 Million ≈ $11.27 Million |
-0.28% |
| 2024-06-30 | AU$15.97 Million ≈ $11.30 Million |
-28.09% |
| 2023-06-30 | AU$22.21 Million ≈ $15.72 Million |
-4.28% |
| 2022-06-30 | AU$23.20 Million ≈ $16.42 Million |
+1.19% |
| 2021-06-30 | AU$22.93 Million ≈ $16.22 Million |
+73.75% |
| 2020-06-30 | AU$13.20 Million ≈ $9.34 Million |
+31.68% |
| 2019-06-30 | AU$10.02 Million ≈ $7.09 Million |
-29.56% |
| 2018-06-30 | AU$14.23 Million ≈ $10.07 Million |
+1.80% |
| 2017-06-30 | AU$13.98 Million ≈ $9.89 Million |
-29.80% |
| 2016-06-30 | AU$19.91 Million ≈ $14.09 Million |
-0.12% |
| 2015-06-30 | AU$19.93 Million ≈ $14.10 Million |
+5.60% |
| 2014-06-30 | AU$18.87 Million ≈ $13.35 Million |
+15.38% |
| 2013-06-30 | AU$16.36 Million ≈ $11.57 Million |
+53.21% |
| 2012-06-30 | AU$10.68 Million ≈ $7.55 Million |
+129.71% |
| 2011-06-30 | AU$4.65 Million ≈ $3.29 Million |
+60.44% |
| 2010-06-30 | AU$2.90 Million ≈ $2.05 Million |
+43.20% |
| 2009-06-30 | AU$2.02 Million ≈ $1.43 Million |
-60.40% |
| 2008-06-30 | AU$5.11 Million ≈ $3.61 Million |
-32.30% |
| 2007-06-30 | AU$7.55 Million ≈ $5.34 Million |
+98.29% |
| 2006-06-30 | AU$3.81 Million ≈ $2.69 Million |
+135.68% |
| 2005-06-30 | AU$-10.67 Million ≈ $-7.55 Million |
+21.21% |
| 2004-06-30 | AU$-13.54 Million ≈ $-9.58 Million |
-100.89% |
| 2003-06-30 | AU$-6.74 Million ≈ $-4.77 Million |
-672.56% |
| 2002-06-30 | AU$1.18 Million ≈ $832.80K |
-90.91% |
| 2001-06-30 | AU$12.96 Million ≈ $9.17 Million |
+4787.61% |
| 2000-06-30 | AU$265.06K ≈ $187.55K |
-97.74% |
| 1999-06-30 | AU$11.75 Million ≈ $8.31 Million |
-18.25% |
| 1998-06-30 | AU$14.37 Million ≈ $10.17 Million |
-17.75% |
| 1997-06-30 | AU$17.48 Million ≈ $12.37 Million |
+622.80% |
| 1995-06-30 | AU$2.42 Million ≈ $1.71 Million |
-55.23% |
| 1994-06-30 | AU$5.40 Million ≈ $3.82 Million |
-33.30% |
| 1993-06-30 | AU$8.10 Million ≈ $5.73 Million |
+40.57% |
| 1992-06-30 | AU$5.76 Million ≈ $4.08 Million |
+3.13% |
| 1991-06-30 | AU$5.58 Million ≈ $3.95 Million |
+14.59% |
| 1990-06-30 | AU$4.87 Million ≈ $3.45 Million |
+13.22% |
| 1989-06-30 | AU$4.30 Million ≈ $3.05 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Pharmx Technologies Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5764.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$93.97 Million | 589.97% |
| Other Comprehensive Income | AU$244.00K | 1.53% |
| Total Equity | AU$15.93 Million | 100.00% |
Pharmx Technologies Ltd Competitors by Market Cap
The table below lists competitors of Pharmx Technologies Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Medicamen Biotech Limited
NSE:MEDICAMEQ
|
$37.33 Million |
|
Aarti Surfactants Limited
NSE:AARTISURF
|
$37.34 Million |
|
Modi Rubber Limited
NSE:MODIRUBBER
|
$37.36 Million |
|
Inter Industries
TA:ININ
|
$37.37 Million |
|
Aviation Links Ltd
TA:AVIA
|
$37.32 Million |
|
NextTrip Inc
NASDAQ:NTRP
|
$37.32 Million |
|
MicroAlgo Inc.
NASDAQ:MLGO
|
$37.31 Million |
|
Janover Inc. Common Stock
NASDAQ:JNVR
|
$37.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharmx Technologies Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 15,972,000 to 15,928,000, a change of -44,000 (-0.3%).
- Net loss of 264,000 reduced equity.
- Other comprehensive income increased equity by 220,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-264.00K | -1.66% |
| Other Comprehensive Income | AU$220.00K | +1.38% |
| Total Change | AU$- | -0.28% |
Book Value vs Market Value Analysis
This analysis compares Pharmx Technologies Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.31x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.52x to 3.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1989-06-30 | AU$0.02 | AU$0.09 | x |
| 1990-06-30 | AU$0.02 | AU$0.09 | x |
| 1991-06-30 | AU$0.02 | AU$0.09 | x |
| 1992-06-30 | AU$17.24 | AU$0.09 | x |
| 1993-06-30 | AU$23.76 | AU$0.09 | x |
| 1994-06-30 | AU$13.62 | AU$0.09 | x |
| 1995-06-30 | AU$0.70 | AU$0.09 | x |
| 1997-06-30 | AU$2.05 | AU$0.09 | x |
| 1998-06-30 | AU$1.76 | AU$0.09 | x |
| 1999-06-30 | AU$1.22 | AU$0.09 | x |
| 2000-06-30 | AU$0.02 | AU$0.09 | x |
| 2001-06-30 | AU$0.76 | AU$0.09 | x |
| 2002-06-30 | AU$0.06 | AU$0.09 | x |
| 2003-06-30 | AU$-0.35 | AU$0.09 | x |
| 2004-06-30 | AU$-0.45 | AU$0.09 | x |
| 2005-06-30 | AU$-0.19 | AU$0.09 | x |
| 2006-06-30 | AU$0.05 | AU$0.09 | x |
| 2007-06-30 | AU$0.09 | AU$0.09 | x |
| 2008-06-30 | AU$0.05 | AU$0.09 | x |
| 2009-06-30 | AU$0.02 | AU$0.09 | x |
| 2010-06-30 | AU$0.01 | AU$0.09 | x |
| 2011-06-30 | AU$0.02 | AU$0.09 | x |
| 2012-06-30 | AU$0.04 | AU$0.09 | x |
| 2013-06-30 | AU$0.06 | AU$0.09 | x |
| 2014-06-30 | AU$0.07 | AU$0.09 | x |
| 2015-06-30 | AU$0.07 | AU$0.09 | x |
| 2016-06-30 | AU$0.07 | AU$0.09 | x |
| 2017-06-30 | AU$0.05 | AU$0.09 | x |
| 2018-06-30 | AU$0.05 | AU$0.09 | x |
| 2019-06-30 | AU$0.04 | AU$0.09 | x |
| 2020-06-30 | AU$0.04 | AU$0.09 | x |
| 2021-06-30 | AU$0.04 | AU$0.09 | x |
| 2022-06-30 | AU$0.04 | AU$0.09 | x |
| 2023-06-30 | AU$0.04 | AU$0.09 | x |
| 2024-06-30 | AU$0.03 | AU$0.09 | x |
| 2025-06-30 | AU$0.03 | AU$0.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharmx Technologies Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3.61%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.18x
- Recent ROE (-1.66%) is above the historical average (-246.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | -32.80% | 0.00% | 0.00x | 4.40x | AU$-1.03 Million |
| 1999 | -27.01% | 0.00% | 0.00x | 1.53x | AU$-4.35 Million |
| 2000 | -4853.86% | -158.70% | 1.03x | 29.81x | AU$-12.89 Million |
| 2001 | -63.55% | -127.64% | 0.27x | 1.82x | AU$-9.53 Million |
| 2002 | -1498.73% | -119.73% | 1.08x | 11.64x | AU$-17.76 Million |
| 2003 | 0.00% | -40.75% | 1.86x | 0.00x | AU$-7.31 Million |
| 2004 | 0.00% | -49.21% | 1.68x | 0.00x | AU$-7.18 Million |
| 2005 | 0.00% | -34.29% | 1.94x | 0.00x | AU$-4.26 Million |
| 2006 | 27.96% | 6.54% | 0.71x | 6.06x | AU$683.40K |
| 2007 | 5.42% | 2.31% | 0.66x | 3.55x | AU$-345.70K |
| 2008 | -61.11% | -16.77% | 0.69x | 5.29x | AU$-3.63 Million |
| 2009 | -518.44% | -52.67% | 1.05x | 9.40x | AU$-10.69 Million |
| 2010 | 38.90% | 5.18% | 1.10x | 6.84x | AU$837.30K |
| 2011 | 37.67% | 8.31% | 1.06x | 4.28x | AU$1.29 Million |
| 2012 | 56.47% | 28.84% | 1.03x | 1.90x | AU$4.96 Million |
| 2013 | 38.85% | 31.34% | 0.80x | 1.55x | AU$4.72 Million |
| 2014 | 22.64% | 22.63% | 0.69x | 1.44x | AU$2.39 Million |
| 2015 | 23.23% | 25.87% | 0.66x | 1.37x | AU$2.64 Million |
| 2016 | 0.14% | 0.17% | 0.60x | 1.31x | AU$-1.96 Million |
| 2017 | -42.05% | -43.51% | 0.68x | 1.41x | AU$-7.27 Million |
| 2018 | 1.76% | 2.25% | 0.57x | 1.39x | AU$-1.17 Million |
| 2019 | -41.96% | -41.49% | 0.67x | 1.50x | AU$-5.21 Million |
| 2020 | 1.33% | 1.93% | 0.48x | 1.45x | AU$-1.14 Million |
| 2021 | 4.76% | 8.59% | 0.41x | 1.37x | AU$-1.20 Million |
| 2022 | 1.09% | 2.11% | 0.39x | 1.33x | AU$-2.07 Million |
| 2023 | -4.73% | -17.46% | 0.16x | 1.64x | AU$-3.27 Million |
| 2024 | -11.08% | -27.27% | 0.22x | 1.87x | AU$-3.37 Million |
| 2025 | -1.66% | -3.61% | 0.39x | 1.18x | AU$-1.86 Million |
Industry Comparison
This section compares Pharmx Technologies Ltd's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $8,552,489
- Average return on equity (ROE) among peers: -90.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharmx Technologies Ltd (PHX) | AU$15.93 Million | -32.80% | 0.18x | $37.33 Million |
| Adheris Health Limited (AHE) | $2.78 Million | -35.73% | 0.18x | $136.67 |
| Alcidion Group Ltd (ALC) | $4.03 Million | -3.69% | 0.00x | $95.02 Million |
| ARTRYA Ltd (AYA) | $16.80 Million | -83.31% | 0.13x | $455.29 Million |
| Beamtree Holdings Ltd (BMT) | $47.14 Million | -10.83% | 0.27x | $24.68 Million |
| Cogstate Ltd (CGS) | $1.84 Million | -38.77% | 0.44x | $291.33 Million |
| Careteq Ltd (CTQ) | $1.52 Million | -4.75% | 2.91x | $2.06 Million |
| Doctor Care Anywhere Group Plc (DOC) | $15.82 Million | -127.77% | 0.24x | $41.51 Million |
| Echoiq Ltd (EIQ) | $22.76 Million | -58.28% | 0.03x | $468.78 Million |
| Emyria Ltd (EMD) | $499.54K | -537.08% | 6.06x | $28.53 Million |
| Enlitic Inc (ENL) | $-27.66 Million | 0.00% | 0.00x | $5.90 Million |
About Pharmx Technologies Ltd
PharmX Technologies Limited, together with its subsidiaries, operates as a technology and software development company in Australia. It also operates PharmX, an electronic ordering and invoicing gateway; PharmX Marketplace, an e-commerce ordering platform; PharmX Analytics which provides insights for operations of supplier and pharmacy customers. The company was formerly known as Corum Group Limi… Read more